Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
· Issued by Trevi Therapeutics, Inc.
Haduvio met the primary endpoint with a statistically-significant reduction (p
